• 1
    Stevens G, Mascarenhas M, Mathers C. Global health risks: progress and challenges. Bull World Health Organ 2009; 87: 646.
  • 2
    Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011; 377: 557-567.
  • 3
    Uwaifo AGI, Editor C, Griffing GT.Obesity. Medscape Reference. 2011. Available at: <>. Accessed 20 August 2011.
  • 4
    Wellman NS, Friedberg B. Causes and consequences of adult obesity: health, social and economic impacts in the United States. Asia Pac J Clin Nutr 2002; 11( Suppl 8): S705-S709.
  • 5
    de Wit L, Luppino F, van Straten A et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 2010; 178: 230-235.
  • 6
    Simon GE, Ludman EJ, Linde JA et al. Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry 2008; 30: 32-39.
  • 7
    Simon GE, Von Korff M, Saunders K et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006; 63: 824-830.
  • 8
    Wadden TA, Stunkard AJ. Social and psychological consequences of obesity. Ann Intern Med 1985; 103: 1062-1067.
  • 9
    Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 2010; 3: 285-295.
  • 10
    Fry J, Finley W. The prevalence and costs of obesity in the EU. Proc Nutr Soc 2005; 64: 359-362.
  • 11
    Bray GA, Paeratakul S, Popkin BM. Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav 2004; 83: 549-555.
  • 12
    Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-172.
  • 13
    Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242.
  • 14
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49-61.
  • 15
    Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160-167.
  • 16
    Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc 1999; 74: 1255-9; quiz 1259.
  • 17
    Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564-575.
  • 18
    US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review. 2009: 180057-180057.
  • 19
    Bachmann C. Ein Fasernkomplex zur Gewichts- reduktion und -kontrolle. Ars Medici thema Phytotherapie 2010: 25-27.
  • 20
    International Association for the Study of Obesity. Overweight and Obesity in the EU27. International Association for the Study of Obesity: London, 2008.
  • 21
    Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc 2002; 102: 1621-1630.
  • 22
    Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17: 241-244.
  • 23
    Drent M, Larsson I, William-Olsson T et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19: 221-226.
  • 24
    US Food and Drug Administration. guidance for industry developing products for weight management guidance for industry developing products for weight management. 2007.
  • 25
    National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Association for the Study of Obesity (NAASO). The practical guide: Identification, evaluation and treatment of overweight and obesity in adults. 2000.
  • 26
    Phelan S, Wadden TA, Berkowitz RI et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond) 2007; 31: 1442-1448.
  • 27
    Jull AB, Rodgers A, Walker N. Honey as a topical treatment for wounds. Cochrane Database Syst Rev 2008: CD005083.
  • 28
    Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125-132.
  • 29
    Romero-Corral A, Virend K, Sierra-Johnson J et al. Accuracy of body mass index to diagnose obesity in the US adult population. Int J Obes (Lond) 2008; 32: 959-966.
  • 30
    Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001; 25: 1095-1099.